The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists

被引：21

作者：

Porter, David W. ^{[1
]}

Bradley, Michelle ^{[1
]}

Brown, Zarin ^{[1
]}

Canova, Riccardo ^{[2
]}

Charlton, Steven ^{[1
]}

Cox, Brian ^{[1
]}

Hunt, Peter ^{[1
]}

Kolarik, David ^{[2
]}

Lewis, Sarah ^{[1
]}

O'Connor, Des ^{[1
]}

Reilly, John ^{[1
]}

Spanka, Carsten ^{[2
]}

Tedaldi, Lauren ^{[1
]}

Watson, Simon J. ^{[1
]}

Wermuth, Roland ^{[2
]}

Press, Neil J. ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England

[2] Novartis Inst BioMed Res, CH-4056 Basel, Switzerland

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 01期

关键词：

CXCR2; Chemokines; Pyrazolopyrimidine; Triazolopyrimidine; Neutrophils; COPD; HIT-TO-LEAD; PULMONARY-DISEASE; INTERLEUKIN-8;

D O I：

10.1016/j.bmcl.2013.11.074

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A hit-to-lead optimisation programme was carried out on the Novartis archive screening hit, pyrazolopyrimidine 2-methyl-5-((phenylthio)methyl)pyrazolo[1,5-a]pyrimidin-7-ol 1, resulting in the discovery of CXCR2 receptor antagonist 2-benzyl-5-(((2,3-difluorophenyl)thio)methyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 14. The SAR was investigated by systematic variation of the pendant thiol, alkyl and pyrimidinol groups. Replacement of the pyrazolopyrimidine core with a triazolo alternative led to a dual series of antagonists with favourable biological and pharmacokinetic properties. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：72 / 76

页数：5

共 50 条

[31] Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin αvβ3) antagonists
Miller, WH
Manley, PJ
Cousins, RD
Erhard, KF
Heerding, DA
Kwon, C
Ross, ST
Samanen, JM
Takata, DT
Uzinskas, IN
Yuan, CCK
Haltiwanger, RC
Gress, CJ
Lark, MW
Hwang, SM
James, IE
Rieman, DJ
Willette, RN
Yue, TL
Azzarano, LM
Salyers, KL
Smith, BR
Ward, KW
Johanson, KO
Huffman, WF
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (08) : 1483 - 1486
[32] The discovery of acylated β-amino acids as potent and orally bioavailable VLA-4 antagonists
Lin, LS
Kopka, IE
Mumford, RA
Magriotis, PA
Lanza, T
Durette, PL
Kamenecka, T
Young, DN
de Laszlo, SE
McCauley, E
Van Riper, G
Kidambi, U
Egger, LA
Tong, XC
Lyons, K
Vincent, S
Stearns, R
Colletti, A
Teffera, Y
Fenyk-Melody, J
Schmidt, JA
MacCoss, M
Hagmann, WK
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (04) : 611 - 614
[33] Discovery of potent, orally active benzimidazole glucagon receptor antagonists
Kim, Ronald M.
Chang, Jiang
Lins, Ashley R.
Brady, Ed
Candelore, Mari R.
Dallas-Yang, Qing
Ding, Victor
Dragovic, Jasminka
Iliff, Susan
Jiang, Guoqiang
Mock, Steven
Qureshi, Sajjad
Saperstein, Richard
Szalkowski, Deborah
Tamvakopoulos, Constantin
Tota, Laurie
Wright, Michael
Yang, Xiaodong
Tata, James R.
Chapman, Kevin
Zhang, Bei B.
Parmee, Emma R.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (13) : 3701 - 3705
[34] CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Dwyer, Michael P.
Yu, Younong
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (13) : 1590 - 1605
[35] CXCR2 receptor antagonists for the treatment of colorectal cancer
Black, Caroline
Venkata, Kalyan Nagulapalli
Wilson, Melissa Labonte
Lenz, Heinz-Josef
Louie, Stan
Petasis, Nicos
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
[36] Phenol-containing antagonists of the CXCR2 receptor
Busch-Petersen, Jakob
Wang, Yonghui
EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (06) : 629 - 637
[37] Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists
Austin, Rupert P.
Bennion, Colin
Bonnert, Roger V.
Cheema, Lal
Cook, Anthony R.
Cox, Rhona J.
Ebden, Mark R.
Gaw, Alasdair
Grime, Ken
Meghani, Premji
Nicholls, David
Phillips, Caroline
Smith, Neal
Steele, John
Stonehouse, Jeffrey P.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (07) : 1616 - 1620
[38] Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists
Ho, KK
Auld, DS
Bohnstedt, AC
Conti, P
Dokter, W
Erickson, S
Feng, DM
Inglese, J
Kingsbury, C
Kultgen, SG
Liu, RQ
Masterson, CM
Ohlmeyer, M
Rong, YJ
Rooseboom, M
Roughton, A
Samama, P
Smit, MJ
Son, E
van der Louw, J
Vogel, G
Webb, M
Wijkmans, J
You, M
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (10) : 2724 - 2728
[39] Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders
Armani, Elisabetta
Rizzi, Andrea
Iotti, Nicolo
Saccani, Francesca
Di Lascia, Maria Rosaria
Tigli, Laura
Pappani, Alice
Marchini, Gessica
Murgo, Annalisa
Capelli, Anna Maria
Delcanale, Maurizio
Puccini, Paola
Villetti, Gino
Civelli, Maurizio
Beato, Claudia
Giuliani, Marta
Mundi, Claudia
Murarolli, Francesca
Pagano, Mafalda
Raveglia, Luca F.
Remelli, Rosaria
Amari, Gabriele
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (08) : 5622 - 5656
[40] Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2
Yang, Michael G.
Xiao, Zili
Zhao, Rulin
Tebben, Andrew J.
Wang, Bei
Cherney, Robert J.
Batt, Douglas G.
Brown, Gregory D.
Cvijic, Mary Ellen
Duncia, John, V
Gallela, Michael A.
Gardner, Daniel S.
Khandelwal, Purnima
Malley, Mary F.
Pang, Jian
Rose, Anne, V
Santella, Joseph B., III
Sarjeant, Amy A.
Xu, Songmei
Mathur, Arvind
Mandlekar, Sandhya
Vuppugalla, Ragini
Zhao, Qihong
Carter, Percy H.
ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (06): : 969 - 975

← 1 2 3 4 5 →